CD274 and neoplasm: Subsequently, a combination of pembrolizumab with different chemotherapy regimens (KEYNOTE-189 and 407 trials) demonstrated a further significant improvement of patient survival irrespective of tumour cell PD-L1 status compared to conventional chemotherapy alone [14, 15].